#Diabetic Neuropathy Market Growth

[health-views-updates]

Diabetic Neuropathy Market Size & Demand Trends for 2024-2032

The Diabetic Neuropathy Market Revenue was valued at USD 4.36 billion in 2023 and is projected to reach USD 8.38 billion by 2032, registering a compound annual growth rate (CAGR) of 7.81% during the forecast period from 2024 to 2032. The rising prevalence of diabetes and an increasing focus on early diagnosis and effective management of diabetic neuropathy are driving market expansion globally.

Market Drivers and Trends

Diabetic neuropathy, one of the most common complications of diabetes, is gaining attention due to its impact on quality of life and healthcare costs. The growing prevalence of diabetes worldwide, coupled with an aging population, is leading to an increased incidence of diabetic neuropathy. This is creating significant opportunities for advancements in treatment options and therapeutic solutions.

Moreover, the market is witnessing substantial investment in research and development aimed at introducing innovative drugs and therapies. Biologics and personalized medicines are gaining traction as they offer promising results in managing the condition effectively. Additionally, the increasing availability of advanced diagnostic tools is helping in the early detection of diabetic neuropathy, thereby enabling timely intervention and better patient outcomes.

Regional Insights

North America dominates the diabetic neuropathy market, owing to a high prevalence of diabetes, robust healthcare infrastructure, and extensive research and development activities. Europe is also a significant contributor, driven by increasing awareness about diabetic complications and supportive government policies. Meanwhile, the Asia-Pacific region is expected to witness rapid growth due to the rising burden of diabetes and improving healthcare access.

Get Free Sample Report@ https://www.snsinsider.com/sample-request/3429

Future Outlook

The diabetic neuropathy market is poised for significant growth over the coming years, driven by advancements in drug discovery and the development of novel treatment modalities. The growing focus on precision medicine and the integration of digital health solutions for patient management are likely to revolutionize the landscape of diabetic neuropathy treatment. Furthermore, collaborations between pharmaceutical companies and research institutions are expected to accelerate innovation and expand access to effective therapies.

About Us

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us

Akash Anand – Head of Business Development & Strategy Email: info@snsinsider.com Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

[versatile-blogger-1]

Global Diabetic Neuropathy Market Is Estimated To Witness High Growth Owing To Increasing Prevalence Of  Diabetes And Rising Demand For Effective Treatment Options

A) Market Overview:

Diabetic neuropathy is a type of nerve damage that can occur as a complication of diabetes. It is caused by high blood sugar levels over a prolonged period of time, which can lead to damage to the nerves throughout the body. Symptoms may include pain, numbness, tingling, and weakness in the affected areas. The market offers various treatment options such as medications, physical therapy, and alternative therapies to manage the symptoms associated with diabetic neuropathy.

B) Market Dynamics:

The two primary drivers contributing to the growth of the Diabetic Neuropathy Market are the increasing prevalence of diabetes and the rising demand for effective treatment options.

The global Diabetic Neuropathy Market is estimated to be valued at USD 3876.6 million in 2023 and is expected to exhibit a CAGR of 6.9% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

The prevalence of diabetes is rapidly increasing globally. According to the International Diabetes Federation, the number of adults living with diabetes is expected to increase from 451 million in 2017 to 693 million by 2045. This significant rise in the diabetic population is anticipated to drive the demand for diabetic neuropathy treatment options.

Moreover, there is a growing demand for effective treatment options for diabetic neuropathy due to the debilitating symptoms and impact on the quality of life of patients. This has led to extensive research and development activities by key players in the market to introduce novel therapeutics and management approaches.

C) Market Key Trends:

One key trend in the Diabetic Neuropathy Market is the increasing adoption of combination therapies. Combination therapies involve the use of two or more drugs with different mechanisms of action to provide enhanced efficacy and better management of symptoms. For instance, the combination of a pain relief medication with an antidepressant or an anticonvulsant medication has shown promising results in managing the pain associated with diabetic neuropathy.

D) SWOT Analysis:

Strength:

Advancements in medical research - Promotes development of novel treatment options.

Increasing healthcare expenditure - Drives market growth.

Weakness:

Lack of awareness about diabetic neuropathy - Hinders early diagnosis and treatment.

Adverse side effects of medications - May limit patient compliance.

Opportunity:

Emerging markets in Asia-Pacific - Untapped potential for market expansion.

Growing focus on personalized medicine - Opens avenues for targeted treatment approaches.

Threats:

Stringent regulatory requirements - This may hinder product approvals.

Competition from alternative treatment options - Poses a challenge to market growth.

E) Key Takeaways:

The global Diabetic Neuropathy Market is expected to witness high growth, exhibiting a CAGR of 6.9% over the forecast period, due to increasing prevalence of diabetes and rising demand for effective treatment options.

The Asia-Pacific region is expected to be the fastest-growing and dominating region in the market, owing to the high prevalence of diabetes and improving healthcare infrastructure.

Key players operating in the global Diabetic Neuropathy Market are Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson, and Janssen Pharmaceuticals.

In conclusion, the Diabetic Neuropathy Market is expected to grow significantly due to the increasing prevalence of diabetes and the rising demand for effective treatment options. Combination therapies and emerging markets in Asia-Pacific present opportunities for market expansion. However, lack of awareness and adverse side effects of medications pose challenges to market growth. Key players in the market are actively engaged in research and development to introduce innovative solutions to address the unmet needs of patients with diabetic neuropathy.

[industrynewsupdates]

Exploring Diabetic Neuropathy Management Market: Trends and Future Outlook

The global diabetic neuropathy management market size was estimated at USD 2.62 billion in 2023 and is expected to grow at a CAGR of 5.8% from 2024 to 2030. Major factors contributing to the market growth include the growing prevalence of diabetes, the rising geriatric population, technological advancements, increased in R&D activities, and the increase in number of product approvals. According to Centers for Disease Control and Prevention (CDC) statistics, approximately 11.6% of the U.S. population, or 38.4 million Americans, live with diabetes and are estimated that half of these individuals are likely to develop diabetic neuropathy at some point during their lifetime.

High prevalence of diabetes is the major factor driving the market growth. Diabetes, when left unmanaged, can lead to a range of serious complications, including peripheral neuropathy. According to the International Diabetes Federation (IDF), 537 million adults worldwide lived with diabetes in 2021, it further states that the number is expected to surge to 642 million by 2040. The prevalence of diabetes is increasing globally, with the most significant rises observed in low- and middle-income countries. The Western Pacific, South Asia, and Europe had the highest numbers of adults living with diabetes in 2021, at 167 million, 88 million, and 59 million respectively.

Gather more insights about the market drivers, restrains and growth of the Diabetic Neuropathy Management Market

Key Diabetic Neuropathy Management Company Insights

The major players in the diabetic neuropathy management market are actively enhancing their product portfolios through various strategies aimed at staying competitive and expanding their market share. This includes continuous product upgrades to incorporate the latest technological advancements, strategic collaborations, and exploring acquisition opportunities. Additionally, obtaining government approvals for their products is crucial to ensure compliance with regulatory standards.

Recent Developments

• In January 2024, The FDA approved Neuralace Medical’s Axon Therapy, a noninvasive treatment for painful diabetic neuropathy. This therapy uses magnetic peripheral nerve stimulation (mPNS) to alleviate chronic pain caused by nerve damage due to diabetes.

• In October 2023, Boston Scientific secured FDA approval for its WaveWriter Alpha spinal cord stimulation device to treat painful diabetic peripheral neuropathy (PDN), a common complication of diabetes that affects the legs and feet. This expanded indication enables Boston Scientific to enter the growing PDN market, which is expected to reach upto USD5 billion in value by Nevro's forecast, alongside competitors Abbott and Medtronic.

• In January 2023, NeuroMetrix launched DPNCheck 2.0, an enhanced point-of-care device for detecting peripheral neuropathy. Using nerve conduction technology, the device offers rapid, accurate, and quantitative testing, improving early detection and staging of neuropathy, including diabetic peripheral neuropathy. It features user-friendly design improvements like real-time nerve response display, a touchscreen interface, and better temperature compensation.

Global Diabetic Neuropathy Management Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global diabetic neuropathy management market report based on devices, application, end-use, and region:

Devices Outlook (Revenue, USD Million, 2018 - 2030)

• Electrical Stimulation Devices

• Neuro Stimulation Devices

• Nerve Conduction Testing Devices

• Other Devices

Application Outlook (Revenue, USD Million, 2018 - 2030)

• Peripheral Neuropathy

• Autonomic Neuropathy

• Proximal Neuropathy

• Mononeuropathy      

End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Home Healthcare

• Other End-use

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

o Mexico

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Argentina

• Middle East & Africa

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Order a free sample PDF of the Diabetic Neuropathy Management Market Intelligence Study, published by Grand View Research.

[insights123]

Diabetic Neuropathy Market to Reach US$ 3876.6 Million by 2022, Exhibiting a CAGR of 6.9%: Coherent Market Insights

The global Diabetic Neuropathy Market is estimated to be valued at US$ 3876.6 million in 2022 and is projected to reach a CAGR of 6.9% over the forecast period 2023-2030

[trendsofmarket]

Analysis of Alpha-glucosidase Inhibitors Market by Size, Supplier, Demand Analysis, Type, Statistics, Regions and Industry Key Manufacture

Research Nester assesses the growth and market size of the global alpha-glucosidase inhibitors market, which is anticipated to be driven by the increasing prevalence of diabetes.

Request for customization @

Research Nester’s recent market research analysis on “Alpha-glucosidase Inhibitors Market: Global Demand Analysis & Opportunity Outlook 2037” delivers a detailed competitors analysis and a detailed overview of the global alpha-glucosidase inhibitors market in terms of market segmentation by drug type, indication, type, distribution channel, and by region.

Personalization Treatment Trend Driving Sales of Diabetes Combination Drugs

Alpha-glucosidase inhibitors are widely used for the treatment of type 2 diabetes, the rising cases of diabetes and increasing diabetes management programs are expected to boost the overall market growth in the coming years. The personalization treatment trend is set to fuel the sales of diabetes combination drugs. Combination therapies offer effective results by achieving better glycemic control. They also aid in mitigating the risk of diabetes-related complications such as cardiovascular diseases, retinopathy, and neuropathy. 

Producers of alpha-glucosidase inhibitors are investing heavily in research and development activities to introduce innovative formulations and delivery mechanisms. The ongoing advancements in alpha-glucosidase inhibitors are foreseen to augment the overall market growth in the coming years.

Growth Drivers:

Rising elderly population who are more susceptible to chronic diseases such as diabetes.

Lucrative opportunities in emerging economies due to high investments in healthcare infrastructure development.

Challenges

Limited awareness is one of the major factors hampering the alpha-glucosidase inhibitors market growth. The lack of information among patients about alpha-glucosidase inhibitor in diabetes management is limiting their sales growth. The availability of several other medications for diabetes treatment is also expected to hinder the sales of alpha-glucosidase inhibitors to some extent in the coming years.

Access our detailed report at:

Based on indication, the type 2 diabetes mellitus segment is expected to capture 89.5% of revenue share by 2037. The rising cases of type 2 diabetes are mainly fuelling the sales of antidiabetic drugs including alpha-glucosidase inhibitors. For instance, the World Health Organization report estimates that around 95% of diabetes patients are suffering from type 2 form of diabetes worldwide. 

By region, North America leads the sales of alpha-glucosidase inhibitors and is estimated to hold a market share of 40.7% by 2037. North America is expanding rapidly in the field of healthcare and the ongoing technological advancements are expected to drive the sales of advanced alpha-glucosidase inhibitors in the coming years. The presence of industry giants and top research organizations is further fuelling the market growth in the region.

This report also provides the existing competitive scenario of some of the key players of the global alpha-glucosidase inhibitors market which includes company profiling of Glenmark Pharmaceuticals Limited, Merck & Co., Inc., Novartis AG, Sanofi SA, Bayer AG, Cipla Limited, Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Lupin Ltd., Alkem Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Unichem Laboratories Ltd.

Request Report Sample@

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@researchnester.com

U.S. Phone: +1 646 586 9123

[marketsndata]

Japan Wound Care Market Analysis 2031

Japan Wound Care Market size was valued at USD 1.61 billion in FY2023, and is expected to reach USD 2.39 billion in FY2031, with a CAGR of 5.1% for the forecast period between FY2024 and FY2031. The Japan wound care market is anticipated to grow, driven by factors such as the growing elderly demographic in Japan, a rising incidence of chronic diseases such as diabetes, and technological advancements. Given the elderly’s susceptibility to skin issues and their need for specialized wound care, the rise in demographics is a significant concern.

According to the Ministry of Internal Affairs and Communications’ population estimates, the number of individuals aged 65 and older increased by 60,000 in 2022, reaching a historical high of 36.27 million. An article published in the Journal of Nursing highlights how skin damage in the elderly, resulting from increased friction and shear forces, contributes to pressure ulcer development. Therefore, the growing elderly population is expected to be a contributing factor to the growth of the market. Furthermore, the implementation of updated wound care management protocols fosters greater unity in healthcare teams and is expected to boost market expansion. In April 2022, the Japanese Society for Burn Injuries (JSBI) released the third iteration of guidelines for inpatient burn injury treatment in Japan. The initiative aims to establish a collective approach to burn care and promote new research to substantiate evidence-based burn care and treatment practices.

Increasing Prevalence of Diabetes

One of the most common outcomes of inadequately managed diabetes mellitus is the development of diabetic foot ulcers. These ulcers typically result from inadequate foot care, peripheral vascular disease, neuropathy, and poor glycemic control. As per data from the IDF Diabetes Atlas 2021, it indicates that an estimated 11.0 million individuals aged 20-79 in Japan had diabetes. Consequently, the substantial diabetes burden in the country elevates the risk of diabetic foot ulcers, necessitating effective wound care and likely contributing to market growth during the forecast period. Moreover, the substantial prevalence and occurrence of diabetic foot ulcers are projected to make the primary wound type, necessitating wound care management in the Japanese population. As per an article published in the Journal of Foot and Ankle Research, the incidence of diabetic foot ulcers in Japan was reported at 2.9 cases per 1000 people. This heightened risk of wound complications associated with diabetes is anticipated to stimulate the demand for wound care management devices in Japan.

Product Launch and Product Approvals

Japan wound care market has witnessed several notable product approvals and launches in recent months. Among these, innovative wound dressings with advanced materials and enhanced antimicrobial properties have gained regulatory approval. These cutting-edge solutions promise improved healing outcomes and infection prevention, addressing the growing need for effective wound management in Japan’s aging population. Additionally, the introduction of smart wound care technologies, including connected devices and remote monitoring systems, has added a new dimension to patient care. These advancements signify a promising era of progress and improved patient outcomes in Japan wound care market.

In June 2021, MIMEDX Group, Inc. obtained regulatory clearance from the Japan MHLW (Ministry of Health, Labor and Welfare) for the introduction of EPIFIX in the Japanese market. EPIFIX received approval for the treatment of challenging-to-heal chronic wounds, notably diabetic foot ulcers. Its purpose is to safeguard the wound bed, promote granulation tissue formation, and provide a biocompatible human extracellular matrix. Consequently, the approval of novel products and their superior benefits are contributing to the increased adoption of wound care solutions.

Collaborations Among Leading Industry Players

Japan wound care market has witnessed several collaborations among leading industry players, fostering innovation and advancements in Japan wound care market. The partnerships aim to address the growing demand for wound care solutions, driven by an aging population and rising incidence of chronic wounds. The collaborations include pharmaceutical companies collaborating with medical device manufacturers to develop integrated wound management systems. Furthermore, wound care product manufacturers often collaborate with research institutions and healthcare providers to conduct clinical trials and studies that enhance product efficacy and safety. These partnerships are accelerating the introduction of cutting-edge wound care technologies, like advanced dressings and regenerative therapies.

In January 2023, MiMedx Group, Inc. entered an exclusive distribution partnership with Gunze Medical Limited to market EPIFIX in Japan, providing a well-established treatment choice for individuals managing chronic wounds.

Impact of COVID-19

The COVID-19 pandemic significantly influenced market growth, primarily due to disruptions in wound care management. For Instance, a study published in the Journal of General Internal Medicine in May 2021 revealed a 61% reduction in diabetic foot care services in Japan during the pandemic. Consequently, the COVID-19 outbreak substantially impacted market growth during this period. Nevertheless, telemedicine services in the region have played a vital role in enabling patients to maintain their healthcare management, including wound care. After the pandemic, areas affected by the pandemic had considerably increased access to telehealth through mobile apps, facilitating improved healthcare management.

Report Scope

“Japan Wound Care Market Assessment, Opportunities and Forecast, FY2017-FY2031”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of the Japan wound care market, industry dynamics and challenges. The report includes market size, segmental shares, growth trends, COVID-19, opportunities and forecast between FY2024 and FY2031. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/japan-wound-care-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: info@marketsandata.com Website: https://www.marketsandata.com

[shubhampawrainfinium]

Comfort Meets Style: Explore Our Diabetic Shoe Collection

The global diabetic shoes market is projected to experience significant growth over the forecast period of 2022-2028. As the global population of individuals with diabetes continues to rise, so does the demand for specialized footwear designed to address the specific needs of diabetic patients, particularly those who are prone to foot injuries or experience changes in foot shape due to the condition.

What Are Diabetic Shoes?

Diabetic shoes are specially designed footwear intended to reduce the risk of skin breakdown in diabetics who have existing foot conditions. These shoes offer extra depth, cushioning, and support to accommodate deformities such as hammertoes or bunions, and they are often prescribed to help prevent complications like ulcers, sores, or amputations that can result from wearing ill-fitting shoes.

Get Sample pages of Report: https://www.infiniumglobalresearch.com/reports/sample-request/29360

Market Dynamics and Growth Drivers

The increasing prevalence of diabetes globally and the need for foot care among diabetic patients are the primary drivers of the diabetic shoes market. Several factors contribute to the market's growth:

Rising Diabetic Population: The global rise in diabetes cases, driven by factors such as aging populations, sedentary lifestyles, and unhealthy diets, is increasing the need for specialized diabetic footwear. Foot complications, such as neuropathy and poor circulation, make regular shoes unsuitable for many diabetics, leading to a growing demand for diabetic shoes.

Foot Injuries and Deformities: Diabetic patients are particularly susceptible to foot injuries and deformities due to nerve damage and poor circulation. This increases the need for shoes that offer better fit, cushioning, and protection compared to standard footwear, reducing the risk of foot ulcers and infections.

Awareness of Diabetic Foot Care: Increased awareness among patients and healthcare professionals regarding the importance of proper foot care for diabetes management is boosting the adoption of diabetic shoes. Preventive measures, including wearing appropriate footwear, are emphasized to avoid severe complications like amputations.

Technological Innovations: Advancements in shoe design, such as the integration of smart insoles, pressure relief materials, and orthotic inserts, are enhancing the effectiveness of diabetic shoes. These innovations are not only improving comfort but also helping monitor foot health, preventing injuries, and promoting healing.

Regional Analysis

North America: The diabetic shoes market in North America is well-established, driven by high diabetes prevalence, advanced healthcare infrastructure, and strong awareness regarding diabetic foot care. The U.S. is the largest market in this region, with numerous companies offering a wide range of diabetic footwear solutions.

Europe: Europe is another significant market, particularly in countries like Germany, France, and the U.K. where diabetes prevalence is high, and healthcare systems emphasize preventive care. Regulatory support for diabetic footwear also contributes to market growth.

Asia-Pacific: The Asia-Pacific region is expected to witness rapid growth in the diabetic shoes market, primarily due to the increasing diabetes population in countries such as China, India, and Japan. Growing healthcare awareness and rising disposable income levels are further supporting market expansion.

Latin America and Middle East & Africa: These regions are gradually adopting diabetic shoes, driven by increasing awareness of diabetes-related foot complications. However, market growth is somewhat restrained by limited access to specialized healthcare services.

Competitive Landscape

The global diabetic shoes market is competitive, with numerous companies offering a variety of products to cater to the needs of diabetic patients. Key players in this market include:

Orthofeet: Known for its wide range of therapeutic shoes designed to offer superior comfort and protection for diabetic patients.

Aetrex: Offers footwear solutions with advanced orthotic technology to prevent pressure points and reduce the risk of foot injuries.

Dr. Comfort: A leading provider of diabetic shoes that combine comfort and style while addressing the specific needs of diabetic patients.

Drew Shoe: Specializes in diabetic shoes that offer extra depth and customized fit, providing enhanced protection for sensitive feet.

Propet USA: Focuses on developing durable and comfortable footwear that supports diabetic foot care.

Report Overview : https://www.infiniumglobalresearch.com/reports/global-diabetic-shoes-market

Challenges and Opportunities

The diabetic shoes market faces certain challenges, such as high costs and the lack of awareness in underdeveloped regions. Additionally, the stigma associated with wearing orthopedic footwear can deter some patients from adopting diabetic shoes.

However, there are significant opportunities for growth. Increasing investments in research and development to create more stylish, comfortable, and functional diabetic footwear are expected to attract a broader consumer base. The integration of smart technology in diabetic shoes, such as sensors to monitor foot pressure and temperature, presents a new frontier for innovation.

Conclusion

The global diabetic shoes market is poised for substantial growth, driven by the rising diabetic population and increasing awareness of the importance of foot care in diabetes management. With technological advancements and a focus on comfort, diabetic shoes are set to play a crucial role in preventing complications and improving the quality of life for individuals with diabetes. As the market continues to evolve, manufacturers that invest in innovation and cater to diverse patient needs will be well-positioned to capitalize on this growing demand. 

[healthcare-skyquest]

Pain Management Drugs Market: Addressing Global Health Needs

The Pain Management Drugs Market plays a crucial role in improving quality of life by providing relief for various acute and chronic pain conditions. As demand for effective pain relief rises, the market is witnessing substantial growth. This article explores the latest trends, market segmentation, key growth drivers, and leading companies in the pain management drugs sector, offering key insights for decision-makers.

Market Overview

According to SkyQuest’s Pain Management Drugs Market report, the market is projected to grow at a CAGR of XX%. Factors such as the increasing prevalence of chronic diseases, advancements in drug formulations, and growing awareness of pain management solutions are driving market growth.

Request Your Free Sample: - https://www.skyquestt.com/sample-request/pain-management-drugs-market

Market Segmentation

By Drug Class:

Opioids: Widely prescribed for severe pain but associated with risks of addiction and side effects.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Commonly used for mild to moderate pain, especially in conditions like arthritis.

Anticonvulsants: Effective in managing nerve pain and neuropathy.

Antidepressants: Used in cases of chronic pain, particularly when linked to depression or anxiety.

Others: Includes topical treatments and alternative pain relief solutions.

By Pain Type:

Chronic Pain: Long-term pain associated with conditions like arthritis, cancer, and back pain.

Acute Pain: Short-term pain caused by injury, surgery, or trauma.

Neuropathic Pain: Arising from nerve damage, often seen in diabetes and multiple sclerosis patients.

By Distribution Channel:

Hospital Pharmacies: Primary distribution point for prescription pain management drugs.

Retail Pharmacies: Widely used for over-the-counter and prescription pain relief medications.

Online Pharmacies: Gaining popularity for the convenience and ease of access they provide to patients.

Key Growth Drivers

Increasing Prevalence of Chronic Conditions: Growing numbers of patients suffering from arthritis, cancer, and neuropathy drive demand for pain relief solutions.

Advancements in Drug Formulations: New drug formulations with fewer side effects and longer-lasting effects are fueling market growth.

Rising Awareness About Pain Management: Increasing patient awareness about the importance of pain management and the availability of various treatment options.

Aging Population: The global aging population is more susceptible to chronic pain, leading to increased demand for pain management drugs.

Take Action Now: Secure Your Report Today - https://www.skyquestt.com/buy-now/pain-management-drugs-market

Leading Companies in the Market

SkyQuest’s report highlights key players leading the Pain Management Drugs Market, including:

Pfizer Inc.

Johnson & Johnson

Eli Lilly and Company

GlaxoSmithKline plc

AbbVie Inc.

AstraZeneca

Sanofi S.A.

Teva Pharmaceutical Industries Ltd.

Bristol-Myers Squibb

Endo Pharmaceuticals

Read More at: - https://www.skyquestt.com/report/pain-management-drugs-market

Challenges and Opportunities

Challenges in the market include the opioid crisis, with governments and regulatory bodies imposing stricter controls on opioid use. However, these challenges open opportunities for the development of non-addictive pain relief alternatives and innovative formulations.

Future Outlook

The Pain Management Drugs Market is expected to experience steady growth, with an increasing focus on non-opioid alternatives and personalized pain management solutions. Companies that invest in research and development of safer, more effective drugs will be at the forefront of this evolving market.

The Pain Management Drugs Market is critical to improving the quality of life for millions of people worldwide. As the market continues to evolve, healthcare decision-makers must stay informed of emerging trends and innovations. For a more in-depth analysis, refer to SkyQuest’s comprehensive Pain Management Drugs Market report.

[health-views-updates]

Diabetic Neuropathy Market Size and Share 2024 | Future Development Analysis and Growth Prospects by 2032

The global Diabetic Neuropathy Market Revenue is set to witness remarkable growth as new treatment innovations and the rising prevalence of diabetes continue to fuel market expansion. A comprehensive report from SNS Insider sheds light on key trends, market drivers, and opportunities in the diabetic neuropathy sector, with market projections indicating substantial revenue growth over the coming years. The report highlights the growing demand for innovative and effective treatment options as diabetic neuropathy cases climb worldwide.

Diabetic neuropathy is one of the most common complications of diabetes, affecting millions of individuals globally. With the increase in diabetic cases, neuropathy incidences have also surged, making the condition a focal point in the global healthcare landscape. Rapid advancements in diabetic treatment and diagnostic solutions have led to a growing need for more targeted and efficient neuropathy therapies, providing significant opportunities for market players. Key pharmaceutical companies, along with emerging biotech firms, are continuously investing in research to bring safer and more effective treatments to market.

The SNS Insider report indicates that the diabetic neuropathy market will benefit significantly from innovations in drug development and patient care techniques. With a focus on personalized medicine and the integration of digital health solutions, healthcare providers can offer more precise treatments and improve patients' quality of life. Furthermore, the increasing availability of advanced therapies in emerging markets is expected to drive further market expansion.

Get Free Sample Report: https://www.snsinsider.com/sample-request/3429

Rising Demand for Treatment Options Amid Growing Diabetic Population

The diabetic neuropathy market is heavily influenced by the global diabetes epidemic. With rising obesity rates, sedentary lifestyles, and unhealthy diets, diabetes cases are on the rise, particularly in developing regions. Diabetic neuropathy is a progressive condition that significantly affects patients’ quality of life, with symptoms ranging from pain and numbness to severe mobility issues. This surge in demand has driven both established pharmaceutical companies and new market entrants to prioritize research and development (R&D) in neuropathy treatments.

The adoption of digital health platforms and mobile health applications is further enhancing patient outcomes. These platforms enable patients to self-monitor blood glucose levels, track symptoms, and manage medication schedules, allowing for more effective management of both diabetes and neuropathy. Such digital solutions, along with wearable technology that monitors vital signs in real time, are revolutionizing patient care and transforming how healthcare providers deliver diabetic neuropathy treatment.

Emerging Trends and Innovations in Diabetic Neuropathy Management

One of the significant trends highlighted in the report is the shift toward personalized medicine and gene therapies. Personalized medicine allows for tailored treatments that take into account individual patient profiles, genetic predispositions, and disease severity, leading to more effective and targeted interventions. Additionally, advances in gene therapy offer the potential to treat the root causes of neuropathy, rather than merely managing symptoms. This breakthrough approach could dramatically change the landscape of diabetic neuropathy treatment over the next decade.

Another noteworthy trend is the development of novel drug delivery systems, such as transdermal patches, which improve patient compliance and comfort. These systems provide a controlled release of medication, potentially minimizing side effects while maximizing therapeutic benefits. Pharmaceutical companies are also exploring combination therapies to address multiple symptoms of diabetic neuropathy simultaneously, which could lead to a more comprehensive treatment approach.

Government Support and Increasing Healthcare Expenditure Boost Market Growth

Government initiatives and increasing healthcare spending are also driving growth in the diabetic neuropathy market. Public health campaigns that promote diabetes awareness, early diagnosis, and preventive measures are helping to identify cases of diabetic neuropathy at earlier stages. Additionally, government grants and funding for diabetes research contribute to the development of new treatments and technologies, further advancing the field.

The growing availability of healthcare services and rising disposable incomes in emerging markets are also significant factors in market expansion. Countries in Asia, Latin America, and Africa are seeing increased investment in healthcare infrastructure, enabling greater access to advanced neuropathy treatments. The expanding reach of healthcare facilities and the availability of specialized diabetes care are expected to further accelerate market growth.

Challenges in the Diabetic Neuropathy Market

Despite the positive outlook, the diabetic neuropathy market faces certain challenges, including the high costs associated with advanced treatments and the limited awareness in some regions. Many treatments, especially those involving advanced therapeutics and digital health devices, remain financially out of reach for a large portion of the global population. Additionally, while diabetes awareness is generally high, the knowledge of diabetic neuropathy and its symptoms is often limited, leading to underdiagnosis and delayed treatment.

Future Outlook

The diabetic neuropathy market is poised for significant growth, with new technologies and treatment methods emerging to meet the needs of a growing patient population. The rise in R&D investments and the adoption of personalized medicine will likely continue to shape the future of this market. With continued innovations and the expansion of healthcare access in emerging markets, the diabetic neuropathy market offers substantial opportunities for both investors and healthcare providers aiming to make a difference in patients’ lives.

About Us

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:

Akash Anand – Head of Business Development & Strategy Email: info@snsinsider.com Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

[colinwilson11]

The Global Ophthalmoplegia Market Will Gain Traction Owing To Increasing Diagnosis Rate

The global ophthalmoplegia market comprises medicines and equipment used for treatment and diagnosis of eye muscle paralysis or limited eye movement, known as ophthalmoplegia. Some key products include diagnostic equipment such as funduscopy, echography and electroretinography machinery used for retina examination. Treatment includes drug therapies such as acetylcholinesterase inhibitors, prostaglandin analogues and alpha agonists. Ophthalmoplegia negatively impacts vision by restricting eye movement and convergence of eyes. It arises due to neuropathies or neuromuscular junction disorders. With growing geriatric population more prone to neurodegenerative diseases and rising healthcare expenditures, diagnosis and treatment seeking rate for ophthalmoplegia is increasing.

The Global Ophthalmoplegia Market is estimated to be valued at US$ 510 Mn in 2024 and is expected to exhibit a CAGR of 7.5% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the global ophthalmoplegia market are Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Pfizer Inc., Bayer AG. These players are engage in new product launches and geographic expansion to gain market share. For instance, in 2023 Novartis launched Rixadyl, a treatment for myasthenia gravis which can potentially treat ophthalmoplegia arising from the condition.

The increasing prevalence of neurological disorders is a major factor driving the demand for ophthalmoplegia treatment. Neuropathies related to diabetes and neurodegenerative diseases like myasthenia gravis and Graves' disease are key causative factors. According to WHO, over 422 million people worldwide have diabetes in 2014, anticipated to rise to over 592 million by 2035. This rises risk of diabetic neuropathies and associated ophthalmoplegia.

Technological advancements are helping improve disease diagnosis. Optical coherence tomography enables high resolution retina imaging without contact. Advances in electrodiagnostic testing aid in accurate neuromuscular junction and neuropathy assessment. Wearable eye trackers also aid in home based monitoring of ophthalmic symptoms, facilitate remote diagnosis.

Market Trends

Increased drug pipeline for orphan ophthalmoplegia indications - Several pharmaceutical companies are developing therapies for rare causes of ophthalmoplegia like Miller Fisher Syndrome. For instance, Alexion Pharma is developing a C5 complement inhibitor ALXN1720 for this syndrome.

Growing diagnostic device industry - Major players are launching portable and affordable devices using technologies like optical coherence tomography, electroretinography for remote patient monitoring and decentralized healthcare access.

Market Opportunities

Emerging markets in Asia Pacific and Latin America present high growth potential for ophthalmoplegia drug makers and device companies. Growing medical tourism and healthcare infrastructure development in these regions can be leveraged.

Shift towards home-based remote care models post Covid - Telehealth platforms enabling virtual consultations and remote monitoring present an opportunity for players to deliver decentralized care using diagnostic devices, virtual training programs for patients.

Impact Of COVID-19 On Global Ophthalmoplegia Market Growth:

The COVID-19 pandemic has significantly impacted the growth of the global ophthalmoplegia market. During the initial phase of the pandemic, lockdowns and social distancing measures implemented worldwide disrupted the supply chains and stalled production activities. This adversely affected the market's growth in the short term. With reduced access to healthcare facilities, diagnosis and treatment of ophthalmoplegia also witnessed delays.

However, with increasing availability of teleconsultation and telemedicine options post lockdowns, the ability to diagnose and manage cases remotely helped the market regain traction. Additionally, rising awareness about the risk of viral infections aggravated by ophthalmoplegia motivated people to seek timely medical care. Government efforts to prioritize availability of essential drugs and treatments for chronic conditions also supported market recovery.

While short-term prospects were impacted, the long-term outlook for the market remains positive. The pandemic highlighted the importance of eye care and ophthalmoplegia management. It is expected that higher focus on preventive healthcare would drive increased adoption of diagnostic tests and treatment regimens. Drug makers are also exploring development of more effective and affordable treatment options to cater to the growing needs of such patients. Overall, with resumption of normal activities and continued medical advancements, the market is projected to regain growth momentum in the coming years.

Geographical Regions With Highest Value Concentration In Global Ophthalmoplegia Market:

North America represents the largest regional market for ophthalmoplegia, in terms of value. Advanced healthcare infrastructure and widespread medical insurance have enabled high adoption of diagnostic procedures and specialty drug therapies in the region. With presence of prominent market players and continuous investments in R&D, the US market within North America dominates global sales. In Europe, government-funded healthcare systems ensure accessibility of treatment options. Germany, France and the UK contribute major shares to the European market. Rising incomes and growing medical tourism are factors fueling the Asia Pacific market growth. China and India have emerged as high potential markets based on their large patient pools. Other regions including Latin America and Middle East & Africa are also witnessing steady expansion of the ophthalmoplegia market.

Fastest Growing Regional Market For Global Ophthalmoplegia:

The Asia Pacific region is poised to register the fastest market growth during the forecast period. This can be attributed to rising incidences of myasthenia gravis and Graves' disease, both of which increase risks of ophthalmoplegia. Improving healthcare infrastructure and expanding insurance coverage have enhanced diagnosis rates across major Asian countries. Additionally, increasing collaboration between international and local pharma companies is facilitating technology transfer and availability of novel drug formulations. Governments are also implementing various initiatives to spread awareness about neurological and ophthalmic conditions. These favorable market determinants are supporting strong sales growth prospects for ophthalmoplegia treatment in Asia Pacific. Other emerging regions including Latin America and Middle East Africa are also projected to provide lucrative opportunities for market expansion in the long run.

Get more insights on this topic: https://www.trendingwebwire.com/global-ophthalmoplegia-market-to-grow-due-to-advancements-in-neurological-disorder-treatments/

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

What Are The Key Data Covered In This Global Ophthalmoplegia Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Global Ophthalmoplegia Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Global Ophthalmoplegia Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Global Ophthalmoplegia Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Global Ophthalmoplegia Market vendors

FAQ’s

Q.1 What are the main factors influencing the Global Ophthalmoplegia Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Global Ophthalmoplegia Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Global Ophthalmoplegia Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[healthcarehubhh]

Diabetic Foot Ulcers Treatment Market will grow at Highest Pace Owing To Rising Incidence of Diabetes

The diabetic foot ulcers treatment market comprises products used for wound care and therapy of ulcers occurring in diabetic patients due to neuropathy and poor circulation. These include wound care dressings, bioactive therapies, and negative pressure wound therapy devices. Diabetic foot ulcers can lead to severe complications including amputation if left untreated and require specialized wound care products to facilitate healing. The global diabetic foot ulcer treatment market projected growth is primarily driven by the increasing diabetes prevalence worldwide. According to IDF, approximately 537 million adults were living with diabetes in 2021 across the globe, and the number is anticipated to rise to 643 million by 2030 and 784 million by 2045. Effective treatment of diabetic foot ulcers plays a crucial role in preventing amputations and maintaining the quality of life of diabetes patients. The Global diabetic foot ulcers treatment market is estimated to be valued at US$ 7.72 Bn in 2024 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030. Key Takeaways Key players operating in the diabetic foot ulcers treatment are 3M Healthcare, Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc., Derma Sciences Inc., Sigvaris Inc., Acelity L.P. Inc., Osiris, Molnlycke Health Care AB, Alkem Laboratories Ltd., Healthium Medtech, Kerecis, Podimetrics, Carmell Corporation, Paracrine, Inc., VIVEX Biologics, Inc., and PolarityTE, Inc. The major players are focusing on new product launches and partnerships to strengthen their market presence. Rising diabetes prevalence worldwide is driving the demand for advanced wound care dressings and bioactive therapies in the market. According to the International Diabetes Federation (IDF), over 537 million adults are estimated to be living with diabetes by 2021, which is projected to rise to 643 million adults by 2030. Advancements in bioengineered skin substitutes and living cell therapies are helping manage diabetic ulcers more effectively and heal them faster. The bioactive therapies segment is anticipated to grow at the fastest pace during the forecast period. Market Trends Increasing Adoption of Regenerative Medicine: Diabetic foot ulcer treatment vendors are increasingly focusing on developing regenerative medicine products and cell-based therapies that can facilitate faster wound healing and close ulcers more permanently. Products like skin substitutes, growth factors, and cell therapies are gaining popularity. Rise of Digital Health Technologies: Companies are integrating technologies like AI, predictive analytics, and digital imaging into wound care products to enable early detection of ulcers and remote monitoring. For example, products allowing wound area and depth measurement using digital imaging and tracking healing progress remotely. This helps improve patient outcomes. Market Opportunities Emerging Nations: Emerging nations in Asia Pacific and Latin America with large diabetic populations and rapidly developing healthcare infrastructure present lucrative opportunities. Product registration and market penetration will be key. Home Healthcare Market: Rising preference for home healthcare and non-surgical ulcer treatment options provides scope for developing advanced wound care dressings and management systems for self-care and remote monitoring at home.

/

[creativecontentcraze]

Peripheral Neuropathy Treatment Market Anticipated To Witness High Growth Owing To Increasing Prevalence Of Diabetes

Peripheral neuropathy treatment involves the treatment of diseases of the peripheral nervous system, which can cause numbness, pain, tingling, and weakness. Peripheral neuropathies can affect both the sensory and motor functions of peripheral nerves. The symptoms can range from mild to severe depending on the cause of neuropathy. The main causes of peripheral neuropathies include diabetes, alcohol consumption, infection such as HIV, and autoimmune disorders.

The global peripheral neuropathy treatment market is estimated to be valued at US$ 2146.54 Bn in 2024 and is expected to exhibit a CAGR of 19% over the forecast period 2024 To 2031. Key Takeaways Key players operating in the peripheral neuropathy treatment market are DMedHOK, Inc., Safecare Technology, Octal IT Solution, McKesson Corporation, LS Retail ehf., Liberty Software, Inc., GlobeMed Group, Datascan, Cerner Corporation, Allscripts Healthcare, LLC, and Epicor Software Corporation, among others. The key players are focusing on new product launches, mergers, acquisitions, and partnerships to gain a competitive advantage in the market. For instance, in April 2022, NeuPath Health launched a new peripheral neuropathy treatment program with advanced diagnostics and integrated care to improve treatment outcomes. The increasing adoption of digital technologies such as AI, analytics, and robotic process automation by healthcare providers provides lucrative growth opportunities in the market. Manufacturers are developing telemetry-enabled, wearable medical devices for remote monitoring and quick response to peripheral neuropathy treatment market symptoms, especially for patients living in remote areas. There is huge potential for market expansion in the Asia Pacific region due to the rising geriatric population, increasing healthcare expenditure, growing prevalence of diabetes, and favorable government policies in countries such as China and India. Key players are focusing on expanding their distribution networks in emerging economies to tap the large patient pool in the Asia Pacific region. Market Drivers Increasing prevalence of diabetes: According to IDF, the global prevalence of diabetes among adults over 18 years of age has risen to 10.5% in 2019 and is projected to increase to 12.2% by 2030. Diabetes is the leading cause of peripheral neuropathy and the increasing diabetes patient pool is driving market growth. Rising healthcare expenditure: Rising healthcare spending on chronic disease management provides an impetus to market growth. For instance, the US healthcare spending is projected to grow at an annual rate of 5.4% from 2020 to 2028 and reach USD 6.2 trillion by 2028. With the aging population and increasing prevalence of peripheral neuropathy, healthcare providers are expected to spend more on neuropathy treatment. Market Restrains High cost of advanced treatment options: Advanced treatment options such as electrical stimulation therapy, electromagnetic therapy, and cryotherapy procedures involve high upfront costs which can hinder patient access and adoption, especially in developing countries. This can restrain market potential to some extent. Limited awareness in developing nations: Peripheral neuropathy awareness still remains relatively low in developing nations where majority cases go undiagnosed due to limited access to healthcare resources. This lack of awareness acts as a market barrier.

Segment Analysis The Peripheral Neuropathy Treatment market can be segmented into drug class, route of administration, distribution channel, and indication. Based on drug class, the market is dominated by pregabalin currently owing to the lack of newer approved products, proven efficacy to alleviate pain associated with neuropathy. However, in the coming years, the antidepressants sub-segment is expected to gain market share due to the off-label usage of antidepressants for the treatment of neuropathy. Based on the route of administration, the oral segment holds a significant share as oral drugs are convenient to use. The topical segment is also growing steadily owing to benefits such as direct site action, avoidance of first-pass metabolism resulting in reduced side effects. In terms of distribution channel, hospital pharmacies maintain dominance as neuropathy patients prefer hospitals for prescription drugs along with medical advice. However, the increasing internet penetration and rising online pharmacy platforms are expected to boost the growth of the retail pharmacy segment during the forecast period. Based on indication, diabetic neuropathy remains the major application area of peripheral neuropathy treatment drugs. This is because diabetic neuropathy is the most common form of neuropathy, accounting for more than 50% of neuropathy cases worldwide. Global Analysis On the regional front, North America is projected to command the maximum share in the global peripheral neuropathy treatment market during the forecast period. The increasing prevalence of diabetes and subsequent rise in diabetic neuropathy cases, expanding geriatric population in the U.S. and Canada and availability of new drugs and treatment options in North America is expected to keep the region at the forefront. However, Asia Pacific is anticipated to witness lucrative growth prospects, especially in India and China. This is credited to the presence of a large patient pool, rising healthcare spending, and improving access to healthcare in APAC countries. At country-level, the U.S. leads the North American peripheral neuropathy treatment market aided by its well-established healthcare system and presence of key market players. Germany dominates the European peripheral neuropathy treatment market attributed to the rising research activities and increasing healthcare spending in the country.

Get More Insights On, Peripheral Neuropathy Treatment Market

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

[marketsndata]

Global Neurological Disorders Diagnostic Market Size, Share, Growth and Forecast 2031

Global neurological disorders diagnostic market is projected to witness a CAGR of 7.56% during the forecast period 2024-2031, growing from USD 7.93 billion in 2023 to USD 14.21 billion in 2031. The market demand for diagnostic neurological disorders is anticipated to thrive drastically in the forecast years due to the rising prevalence of neurological disorders and the growing interest of investors and market players.

Neurological disorders, as a medical term, refers to the disorders that affect the brain besides the nerves distributed all over the human body and the spinal cord. Such disorders may have varied symptoms due to structural, biochemical, or electrical abnormalities in the brain, spinal cord, or other nerves. Examples of such disorders are paralysis, muscle weakness, poor coordination, loss of sensation, seizures, confusion, pain, and disturbed levels of consciousness. For instance, according to The Lancet Neurology report, over 1 in 3 people around the world are affected by neurological conditions, meaning it is now the leading cause of illness and disability worldwide. While brain diseases, disorders, and injuries affect everyone around the globe, it is estimated that more than 80% of neurological deaths and health loss occur in low-income and middle-income countries. High-income countries have up to 70 times more neurological professionals per 100,000 population than low-and middle-income countries. The prevalence of neurological disorders such as diabetes neuropathy and Alzheimer’s disease conditions has led to a greater need for neurological disorders diagnosis. These factors are expected to boost the global neurological disorders diagnostic market during the forecast period.

Rising Prevalence of Neurological Disorders

The rising prevalence of neurological disorders is a significant growth driver for the neurological disorder diagnostic market. With the growing prevalence of Alzheimer’s, Parkinson’s, epilepsy, and multiple sclerosis worldwide, the demand for precise early-stage diagnostic tools to detect such diseases is on the rise. This is particularly true for aging populations whose neurological disorders are on the rise. Higher consciousness among medical practitioners and patients regarding neurological disorders has also increased the demand for more advanced diagnostic solutions. Furthermore, the influx of advanced technologies and methodologies by the service providers in the diagnosis process is increasing the scope of this market for neurological disorder diagnostics. This rising prevalence not only underscores the urgency for effective diagnostics but also drives research and development efforts to improve the tools and techniques used to identify and manage these complex disorders. For instance, on 10 May 2023, scientists from UNSW Sydney, along with collaborators at Boston University, developed a tool that showed early promise in detecting Parkinson’s disease years before the first symptoms started appearing.

Technological Advancements in Neurological Disorder Testing

Technological advancements in neurological disorder testing are a key growth driver for the neurological disorder diagnostic market. Advances in imaging techniques, such as high-resolution MRI and functional imaging, improve the accuracy and efficiency of diagnosis. Advances in neurophysiological testing, including EEG and QEEG, and evoked potential studies allow for detecting abnormalities in brain and nervous system disorders. Integrating AI and ML into diagnostic processes continues to revamp the landscape by enabling a higher degree of precision in analyzing complex data and facilitating early detection. Such technologies improve diagnostics outcomes and allow for efficient workflows within a clinical setting, thus making it easier for healthcare providers to provide timely and accurate care. Since these progressions continue to rise, there will be robust growth in the market for neurological disorder diagnosis, which will consume the new challenges facing diagnosis methods. For instance, on December 21, 2023, Quibim, a company pioneering in imaging biomarkers for Precision Medicine, received approval from the U.S. Food and Drug Administration for QP-Brain, an AI-based software to identify early-stage neurodegenerative diseases. Most disease detection in this field is through qualitative analysis carried out by radiologists and neurologists. This purely human-centered approach means that neuro diseases are often only detected at their later stages. Healthcare institutions, therefore, need very advanced and versatile quantitative AI-based tools that can also provide secure transfer and storage of patients’ data and augment the workflow of clinicians.

Neuroimaging Technologies Segment to Dominate the Neurological Disorders Diagnostic Market

The neuroimaging technologies segment is expected to dominate the neurological disorders diagnostic market during the forecast period. Further, the advancements in neuroimaging technologies and new and innovative technologies by key players in the market are expected to propel market growth. Techniques such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) in neuroimaging form the critical anatomical evidence for accurate and timely diagnosis of all neurological disorders. These methods provide detailed information about the structure and function of the brain, where doctors can find abnormalities attributed to disorders, including Alzheimer’s disease, tumors, and stroke. The advancement of imaging technology, from higher resolution to functional imaging modalities, has led to improved diagnostic accuracy and therapeutic planning. Increased neurological disorders and the growing need for early diagnosis further favor this growth in demand for neuroimaging modalities. Healthcare providers will increasingly use advanced imaging techniques to support their diagnoses, so neuroimaging technologies will become extremely important in defining the market’s future for neurological disorder diagnostics. For instance, on 27 February 2024, Philips, a global leader in health technology, announced major enhancements to its Image Guided Therapy System – Azurion – with the launch of its new Azurion neuro biplane system. The new image-guided therapy system is a comprehensive interventional solution in patients with stroke or other neurovascular diseases, supporting confident diagnosis, image guidance, and therapy assessment.            

North America Dominates Neurological Disorders Diagnostic Market 

North America is the biggest market in terms of neurological disorder diagnostics. Generally, the developed health infrastructures, huge investments in research and development, and a high incidence of neurological conditions are dominant in the region. The incidence of chronic neurodegenerative diseases will at least double within the next two decades. In 2023, the two most prevalent neurological diseases were Alzheimer’s disease and Parkinson’s disease. An estimated 6.7 million Americans 65 years of age and older have Alzheimer’s disease. If medical developments are not achieved to prevent, halt, or even cure AD, this number may increase to 13.8 million by the year 2060. In addition, the good network of hospitals and diagnostic centers found in this region have cutting-edge technologies, such as advanced neuroimaging and neurophysiological testing methods, which help in proper and timely diagnosis.

Increased awareness and the advertisement of neurological disorders have led to an increased demand for service diagnosis. The government’s increasing initiative through huge investments in researching neurological disorders further fuels the growth of the market toward innovation in diagnostic tools and treatments. For instance, on 30 April 2024, NeuroClues, a French-Belgian medtech company that specializes in the diagnosis of neurodegenerative diseases, announced that it has successfully closed a new funding round of around USD 5 million. It was led by White Fund and the European Commission’s EIC Accelerator program, along with existing investors.

Download Free Sample Report

Future Market Scenario (2024-2031F)

The future market scenario regarding the neurological disorders diagnostic market is promising with robust growth rates, driven primarily by ongoing technological advancement and a need for faster and more precise diagnoses. These ongoing innovations in neuroimaging, biomarker identification, and artificial intelligence will further evolve; healthcare providers will become more adept at detecting and managing conditions more precisely. The prevalence of conditions such as Alzheimer’s, Parkinson’s, and multiple sclerosis is expected to continue rising and spreading among elders, boosting market growth even more. There is going to be an increased focus on personalized medicine and a patient-centric approach that would increase the demand for tailor-made diagnostic applications for improving patient outcomes. Continuous awareness and investment in neuro-health and high growth in the market would be seen further changing the diagnostic landscape of neurological disorders in the coming years. For instance, on May 9, 2024, Danaher Corporation, a global science and technology innovator, launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild Traumatic Brain Injury (TBI).             

Report Scope

“Neurological Disorders Diagnostic Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global neurological disorders diagnostic market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/neurological-disorders-diagnostic-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: info@marketsandata.com Website: https://www.marketsandata.com

[cardiologistdrfarhanshikoh]

How Uncontrolled Diabetes Damages Our Body

Uncontrolled diabetes can have severe impacts on various parts of our body. Here's how it affects different systems:

Cardiovascular System: Diabetes increases the risk of heart disease by causing damage to blood vessels and nerves that control the heart. It can lead to high blood pressure, coronary artery disease, and even heart attacks.

Eyes: High blood sugar levels can cause damage to the blood vessels in the retina, leading to diabetic retinopathy. This condition can result in vision loss and, in severe cases, blindness.

Teeth: Poorly managed diabetes can lead to higher levels of glucose in saliva, which promotes the growth of harmful bacteria. This increases the risk of gum disease, infections, and tooth decay.

Nervous System: Diabetes can cause neuropathy, a condition characterized by nerve damage. This can result in numbness, tingling, and pain, particularly in the hands and feet, and may even lead to severe complications like foot ulcers.

Mental Health: The stress of managing diabetes, combined with its physical effects, can contribute to mental health issues such as depression and anxiety. The constant monitoring and need for lifestyle changes can be overwhelming for many.

For comprehensive care and consultation on managing diabetes and preventing its complications, visit Dr. Md. Farhan Shikoh, MBBS, MD (Medicine), DM (Cardiology), at Sukoon Heart Care, Sainik Market, Main Road, Ranchi, Jharkhand: 834001. You can also reach out at 6200784486 or visit drfarhancardiologist.com for more information.

[tejalbele-2024]

Pain Management drugs Market valued at $71,431.85 million in 2019, and is projected to reach $91,649.16 million

The global pain management drugs market was valued at $71,431.85 million in 2019, and is projected to reach $91,649.16 | CAGR of 3.8% from 2020 to 2027.

PORTLAND, OREGON, UNITED STATES, February 1, 2024 /EINPresswire.com/ -- Pain is a disturbing sensory and emotional sensation that results from tissue damage or disease. In addition, different disorders may cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer. The length of pain ranges from acute pain for short term to chronic pain for long term. Acute pain can be mild and lasts for only a moment or for weeks, or months. Chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. A variety of drugs are used to manage pain resulting from inflammation in response to tissue damage, chemical agents/pathogens (nociceptive pain) or nerve damage (neuropathic pain). Most drugs act by binding to protein targets on cell membranes and affecting biochemical processes of the body.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/404

Rise in geriatric population is the major factor that drives growth of the global pain management drugs market as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel growth of the pain management drugs market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.

𝐃𝐫𝐮𝐠 𝐜𝐥𝐚𝐬𝐬 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐫𝐞𝐯𝐢𝐞𝐰 By drug class, the opioids segment was the largest contributor to the market in 2019, owing to high efficiency of opioids to relieve pain in major chronic conditions. The anesthetics segment is anticipated to possess highest growth rate during the forecast period.

𝐃𝐨 𝐘𝐨𝐮 𝐇𝐚𝐯𝐞 𝐀𝐧𝐲 𝐐𝐮𝐞𝐫𝐲 𝐎𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐪𝐮𝐢𝐫𝐞𝐦𝐞𝐧𝐭? 𝐀𝐬𝐤 𝐭𝐨 𝐎𝐮𝐫 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐄𝐱𝐩𝐞𝐫𝐭: https://www.alliedmarketresearch.com/purchase-enquiry/404

𝐊𝐞𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 ELI LILY AND COMPANY MERCK & CO. INC. PFIZER INC. ABBOTT LABORATORIES GLAXOSMITHKLINE PLC (GSK) MYLAN N.V. NOVARTIS INTERNATIONAL AG PURDUE PHARMA L.P. JOHNSON & JOHNSON ENDO HEALTH SOLUTIONS INC. (ENDO INTERNATIONAL PLC.)

𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐅𝐨𝐫 𝐒𝐭𝐚𝐤𝐞𝐡𝐨𝐥𝐝𝐞𝐫𝐬 The study provides an in-depth analysis of the global pain management drug market along with the current trends and future estimations to elucidate the imminent investment pockets. A comprehensive analysis of the factors that drive and restrict the pain management drugs market growth is provided in the report. The pain management drugs market forecast is studied from 2020 to 2027 Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities. Extensive analysis of the key segments of the industry helps to understand the application and products of pain management used across the globe. Key market players and their strategies have been analysed to understand the competitive outlook of the pain management drugs market.

𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐑𝐞𝐯𝐢𝐞𝐰 The demand for pain management drugs has increased rapidly over recent years. Pain can be caused due to various reasons such as chronic diseases, cancer, and surgeries. Thus, these segments are the largest contributors to the market growth. Presence of large geriatric population base, rise in global prevalence of cancer, and availability of pipeline drugs that pose to be promising treatment options for patients with chronic diseases contribute to growth of the market.

However, patent expiration of major best-seller drugs such as pregabalin and duloxetine by Pfizer and Eli Lilly & Co., respectively, and availability of alternative therapies such as acupuncture, massage, and medical devices hamper the market growth.

Employment of pain management drugs is the highest in North America, owing to increase in adoption of these drugs, high prevalence of chronic diseases, and increase in disposable income of customers. In addition, presence of a large geriatric population and favorable regulatory & healthcare reforms such as the U.S. Patient Protection and Affordable Care Act of 2010 supplement the market growth.

Although the use of pain management drugs in Asia-Pacific and LAMEA is low, the adoption rate is expected to increase, owing to rise in disposable income and surge in incidences of chronic diseases. China and India are potential markets in Asia-Pacific. Moreover, increase in R&D investments, upsurge in healthcare expenditure, and rise in government funding & initiatives propel the market growth in Asia-Pacific.